192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 192,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,852,000. Celldex Therapeutics makes up 1.2% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 14th biggest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock worth $98,098,000 after purchasing an additional 12,213 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Celldex Therapeutics by 23.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock worth $89,890,000 after buying an additional 676,771 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Celldex Therapeutics by 50.8% in the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock worth $63,579,000 after buying an additional 847,264 shares during the last quarter. Deep Track Capital LP acquired a new stake in Celldex Therapeutics in the 4th quarter worth about $38,919,000. Finally, Rock Springs Capital Management LP boosted its stake in Celldex Therapeutics by 10.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company’s stock worth $30,885,000 after buying an additional 118,404 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CLDX shares. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a “buy” rating and a $64.00 price target on the stock. UBS Group decreased their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $20.45 on Friday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -7.96 and a beta of 1.39. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The business’s 50-day simple moving average is $18.91 and its 200-day simple moving average is $22.58.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.